Smith & Nephew plc (SNNUF)
OTCMKTS · Delayed Price · Currency is USD
18.20
0.00 (0.00%)
Sep 11, 2025, 8:00 PM EDT
Smith & Nephew Employees
Smith & Nephew had 17,349 employees as of December 31, 2024. The number of employees decreased by 1,103 or -5.98% compared to the previous year.
Employees
17,349
Change (1Y)
-1,103
Growth (1Y)
-5.98%
Revenue / Employee
$349,647
Profits / Employee
$28,882
Market Cap
16.53B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 17,349 | -1,103 | -5.98% |
Dec 31, 2023 | 18,452 | -560 | -2.95% |
Dec 31, 2022 | 19,012 | 643 | 3.50% |
Dec 31, 2021 | 18,369 | 455 | 2.54% |
Dec 31, 2020 | 17,914 | 277 | 1.57% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Jushi Holdings | 1,234 |
Smith & Nephew News
- 2 days ago - Smith+Nephew (SNN) Highlights Advances in REGENETEN Implant Technology - GuruFocus
- 3 days ago - Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant - GlobeNewsWire
- 10 days ago - What Does the Market Think About Smith & Nephew? - Benzinga
- 10 days ago - Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System - GlobeNewsWire
- 5 weeks ago - Smith & Nephew: Doing Better And Still Offers Value - Seeking Alpha
- 5 weeks ago - Smith & Nephew plc 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Top 2 Health Care Stocks You May Want To Dump In Q3 - Benzinga